Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma

Part of paid clinical trials in Encinitas, California.

Sponsor
San Diego Pacific Oncology & Hematology Associates
Study ID
NCT00538005
Phase
PHASE1/PHASE2
Status
Unknown

Conditions

  • Melanoma (Skin)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • bevacizumab — BIOLOGICAL
  • oxaliplatin — DRUG
  • sorafenib tosylate — DRUG

Study Details

RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of malignant melanoma by blocking blood flow to the tumor. Drugs used in chemotherapy, such as oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sorafenib together with bevacizumab and oxaliplatin may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side-effects and best dose of sorafenib when given together with bevacizumab and oxaliplatin and to see how well it works in treating patients with metastatic malignant melanoma.

Key Dates

First listed
Oct 2, 2007
Start date
May 31, 2007
Status verified
Jul 2009
Primary completion
Jul 31, 2009

Study Design

Enrollment
54 participants (estimated)
Primary purpose
TREATMENT

Primary Outcome Measure

Maximum tolerated dose of sorafenib tosylate when administered with bevacizumab and oxaliplatin

Locations (1)

FacilityCityStateZIPSite coordinators
San Diego Pacific Oncology and Hematology Associates, Incorporated - EncinitasEncinitasCalifornia92024
Edward F. McClay, MD
760-452-3340

Find similar trials in Encinitas, CA

Related Studies